

US007326708B2

US 7,326,708 B2

Feb. 5, 2008

(12) United States Patent Cypes et al.

(54) PHOSPHORIC ACID SALT OF A DIPEPTIDYL PEPTIDASE-IV INHIBITOR

(75) Inventors: **Stephen Howard Cypes**, Santa Clara, CA (US); **Alex Minhua Chen**, Metuchen, NJ (US); **Russell R. Ferlita**, Westfield, NJ (US); **Karl Hansen**,

Atlantic Highlands, NJ (US); Ivan Lee, Piscataway, NJ (US); Vicky K. Vydra, Fair Lawn, NJ (US); Robert M. Wenslow, Jr., East Windsor, NJ (US)

(73) Assignee: Merck & Co., Inc., Rahway, NJ (US)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35

U.S.C. 154(b) by 657 days.

(21) Appl. No.: 10/874,992

(22) Filed: Jun. 23, 2004

(65) Prior Publication Data

US 2005/0032804 A1 Feb. 10, 2005

Related U.S. Application Data

- (60) Provisional application No. 60/482,161, filed on Jun. 24, 2003.
- (51) **Int. Cl. A61K 31/495** (2006.01) **C07D 471/04** (2006.01)

See application file for complete search history.

(56) References Cited

(10) Patent No.:

(45) Date of Patent:

U.S. PATENT DOCUMENTS

 6,479,692
 B1 * 11/2002
 Ekwuribe et al.
 558/413

 6,699,871
 B2
 3/2004
 Edmondson et al.

 2003/0100563
 A1
 5/2003
 Edmondson et al.

 2006/0287528
 A1 * 12/2006
 Wenslow et al.
 544/350

 2007/0021430
 A1 * 1/2007
 Chen et al.
 514/249

FOREIGN PATENT DOCUMENTS

WO WO 2005/072530 A1 8/2005 WO WO 2006/033848 A1 3/2006

OTHER PUBLICATIONS

Edmondson, S.D., Drug Data Report, vol. 25, No. 3, pp. 245-246 (2003).

Database Prous DDR Online—Database Accession No. 2003: 3561.

* cited by examiner


Primary Examiner—James O. Wilson Assistant Examiner—Ebenezer Sackey (74) Attorney, Agent, or Firm—Philippe L. Durette; Catherine D. Fitch

(57) ABSTRACT


The dihydrogenphosphate salt of 4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro [1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine is a potent inhibitor of dipeptidyl peptidase-IV and is useful for the prevention and/or treatment of non-insulin dependent diabetes mellitus, also referred to as type 2 diabetes. The invention also relates to a crystalline monohydrate of the dihydrogenphosphate salt as well as a process for its preparation, pharmaceutical compositions containing this novel form and methods of use for the treatment of diabetes, obesity, and high blood pressure.

24 Claims, 5 Drawing Sheets





















DOCKET

Explore Litigation Insights



Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time** alerts and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.

